HLA class I and II alleles and response to treatment with interferon-beta in relapsing–remitting multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HLA class I and II alleles and response to treatment with interferon-beta in relapsing–remitting multiple sclerosis

Published:2009-05 Issue:1-2 Volume:210 Page:116-119
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Comabella M.,Fernández-Arquero M.,Río J.,Guinea A.,Fernández M.,Cenit M.C.,de la Concha E.G.,Montalban X.

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference19 articles.

1. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis;Brynedal;PLoS ONE,2007

2. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis;Byun;Arch. Neurol.,2008

3. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes;Cunningham;Clin. Pharmacol. Ther.,2005

4. HLA class II and response to interferon-beta in multiple sclerosis;Fernández;Acta Neurol. Scand.,2005

5. HLADRB1⁎1501 and response to copolymer-1 therapy in relapsing–remitting multiple sclerosis;Fusco;Neurology,2001

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression;Frontiers in Immunology;2024-06-07

2. Unveiling sex-based impact of TYK2 rs2304256 polymorphism on interferon beta-1alpha responsiveness in COVID-19 patients;Gene Reports;2023-12

3. HLA-DRB1*1501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis;Multiple Sclerosis Journal;2022-11-18

4. Long-term use of interferon-β in multiple sclerosis increases Vδ1−Vδ2−Vγ9− γδ T cells that are associated with a better outcome;Journal of Neuroinflammation;2019-09-13

5. Genetic Markers for Personalized Therapy of Polygenic Diseases: Pharmacogenetics of Multiple Sclerosis;Molecular Biology;2019-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3